-
Regeneron Snags Upgrade On Reduced Prospects For Rival Eye Disorder Drug
Tuesday, February 25, 2020 - 12:46pm | 422Read More...One's pain is another's gain, and this phrase ringed in true in the case of Regeneron Pharmaceuticals Inc (NASDAQ: REGN). Jefferies deemed fit to upgrade shares on improved prospects for its eye disorder drug Eylea following disclosure of adverse events associated with Novartis AG's (...
-
Jefferies Calls Bluebird Bio The 'Star' Of This Year's ASH Meeting
Monday, December 11, 2017 - 11:53am | 460Read More...Bluebird bio Inc (NASDAQ: BLUE)'s encouraging data release over the weekend has many experts and Wall Street analysts excited about the company's prospects in treating sickle cell disease. The Analyst Jefferies' Biren Amin upgraded bluebird's stock rating from Hold to Buy with a...
-
Bellicum Pharmaceuticals Q1 Miss Doesn't Matter, As Long As Pipeline Remains On Track
Tuesday, May 9, 2017 - 12:19pm | 385Read More...Quarterly earnings reports matter a lot more for some companies than others. According to Wall Street analysts, investors should look beyond Bellicum Pharmaceuticals Inc (NASDAQ: BLCM)’s first-quarter earnings miss and focus on its drug pipeline, which includes leading cancer treatment...
-
Low Odds Court Ruling Against Regeneron Get Reversed On Appeal
Friday, January 6, 2017 - 12:48pm | 359Read More...Following the district court ruling in favor of Amgen, Inc. (NASDAQ: AMGN), Jefferies said in a note on Thursday that the odds of an appeal by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY) were low. Analyst Biren Amin noted that the District Court of Delaware...
-
Jefferies Sees Zynerba Shares More Than Doubling From Here
Tuesday, December 6, 2016 - 11:40am | 298Read More...At a recent AES (American Epilepsy Society) event, Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presented safety data from Phase I studies for ZYN002 CBD gel in healthy volunteers and patients with epilepsy. “We believe the data presented at AES supports the outlook for the PII trial,”...
-
Kite Pharma Spiking After Release Of Positive Clinical Data
Tuesday, September 27, 2016 - 10:57am | 354Read More...Kite Pharma Inc (NASDAQ: KITE) announced positive topline data from the PII ZUMA-1 study in NHL. “We view the 3-month CR rate across the entire ZUMA-1 cohort as favorable and suggestive of a durable response,” Jefferies’ Biren Amin said in a report. He maintained a Buy rating...
-
Jefferies Upgrades AveXis To Buy Following Positive AVXS-101 Data, Doc Feedback
Friday, August 12, 2016 - 9:03am | 350Read More...The updated AVXS-101 data released by AveXis Inc (NASDAQ: AVXS) suggests that the FDA may allow for a single-arm pivotal trial in SMA Type 1, Jefferies’ Biren Amin said in a report. He upgraded the rating on the company from Hold to Buy, while maintaining the price target at $42....
-
Jefferies Lifts Target On Medivation To $52 From $39 As 'Xtandi Looking Better'
Monday, May 2, 2016 - 2:28pm | 388Read More...Jefferies raised the price target of Medivation Inc (NASDAQ: MDVN) shares to $52 from $39 after its survey showed "meaningful improvement" in the market for Xtandi on almost all fronts. The Physician Survey Jefferies conducted a physician survey "to gauge the outlook for Medivation's Xtandi given...
-
Buy ImmunoGen On Transformational Products, Jefferies Says
Wednesday, November 25, 2015 - 11:45am | 264Read More...The share price of ImmunoGen, Inc. (NASDAQ: IMGN) has surged 130.49 percent year-to-date, from $6.10 on December 31, 2014. Jefferies’ Biren Amin has reinitiated coverage of the company with a Buy rating and price target of $16. Since the company began partnering Kadcyla royalties...
-
Heron Therapeutics Has Even More Upside, 'Robust' Data Shows
Wednesday, September 23, 2015 - 11:03am | 250Read More...Heron Therapeutics Inc (NASDAQ: HRTX) shares have appreciated 27 percent in the last three months and touched a high of $42 on September 8. Jefferies’ Biren Amin maintained a Buy rating on the company, while raising the price target from $47 to $58. Positive data for HTX-011 in...
-
1,800% In Two Days: The Saga Of Aquinox Pharmaceuticals
Monday, August 10, 2015 - 11:46am | 356Read More...Shares of Aquinox Pharmaceuticals Inc (NASDAQ: AQXP) skyrocketed more than 350 percent Monday morning, hitting a 52-week high of $55.75. The stock was trading at less than $2 per share last Thursday -- that's not a typo. Midway through Monday's trading, the stock is near the $38 mark. On Friday...
-
Kite Pharma Shares Its Vision: Here's How Wall Street Is Reacting
Wednesday, June 24, 2015 - 12:15pm | 290Read More...Kite Pharma Inc (NASDAQ: KITE) hopes to seek regulatory approval next year for a treatment for a form of lymphoma, an analyst said Wednesday. Jefferies' Biren Amin reiterated a Buy rating and $83 target following Kite executives meeting with analysts in New York Tuesday. Canaccord's...
-
UPDATE: Jefferies Initiates Coverage On Bellicum Pharmaceuticals On Position To Be Leading Player
Monday, January 12, 2015 - 10:01am | 110Read More...In a report published Monday, Jefferies analyst Biren Amin initiated coverage on Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) with a Buy rating and $35.00 price target. In the report, Jefferies noted, “BLCM appears poised to be a leading player in the development of suicide safety switches for T-...
-
UPDATE: Jefferies Initiates Coverage On Xenon Pharmaceuticals On Multiple Positive Factors
Monday, December 1, 2014 - 11:05am | 121Read More...In a report published Monday, Jefferies analyst Biren Amin initiated coverage on Xenon Pharmaceuticals (NASDAQ: XENE) with a Buy rating and $16.00 price target. In the report, Jefferies noted, “XENE shares may appreciate over the next 12-18 months from multiple PI/II readouts. Also, XENE has...
-
UPDATE: Jefferies Downgrades Onyx Pharmaceuticals on Limited Upside
Friday, August 2, 2013 - 8:08am | 121Read More...In a report published on Friday, Jefferies analyst Biren Amin downgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Buy to Hold and raised the price target on the company from $104 to $132. In the report, Jefferies stated, "Given the M&A interest in ONXX we are downgrading to Hold on...
